Commodore Capital as of March 31, 2026
Portfolio Holdings for Commodore Capital
Commodore Capital holds 36 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Relay Therapeutics (RLAY) | 9.8 | $169M | 17M | 9.95 | |
| Alkermes SHS (ALKS) | 8.6 | $149M | 4.2M | 35.36 | |
| Enliven Therapeutics (ELVN) | 7.4 | $128M | 3.3M | 39.20 | |
| Cogent Biosciences (COGT) | 6.4 | $111M | 2.9M | 38.49 | |
| Spyre Therapeutics Com New (SYRE) | 5.6 | $97M | 1.9M | 50.44 | |
| Tyra Biosciences (TYRA) | 5.5 | $95M | 2.5M | 38.30 | |
| Celldex Therapeutics Com New (CLDX) | 4.9 | $86M | 2.7M | 31.72 | |
| Nuvalent Inc-a (NUVL) | 4.9 | $85M | 834k | 102.45 | |
| Amylyx Pharmaceuticals (AMLX) | 4.5 | $79M | 5.7M | 13.90 | |
| Kymera Therapeutics (KYMR) | 3.6 | $63M | 750k | 83.29 | |
| Alto Neuroscience Com Shs (ANRO) | 3.5 | $61M | 2.7M | 22.48 | |
| Pharvaris N V (PHVS) | 3.1 | $54M | 1.9M | 28.25 | |
| Erasca (ERAS) | 3.0 | $51M | 3.2M | 16.18 | |
| Damora Therapeutics Com New (DMRA) | 2.9 | $50M | 1.9M | 25.90 | |
| Xenon Pharmaceuticals (XENE) | 2.8 | $48M | 825k | 58.15 | |
| Definium Therapeutics Com Shs (DFTX) | 2.2 | $38M | 2.0M | 18.90 | |
| Lb Pharmaceuticals Com Shs (LBRX) | 2.1 | $37M | 1.5M | 24.66 | |
| Eyepoint Com New (EYPT) | 2.1 | $36M | 2.8M | 12.89 | |
| Nurix Therapeutics (NRIX) | 2.0 | $35M | 2.3M | 15.50 | |
| Corvus Pharmaceuticals (CRVS) | 1.9 | $33M | 2.3M | 14.63 | |
| Assembly Biosciences Com New (ASMB) | 1.6 | $28M | 1.0M | 27.75 | |
| Perspective Therapeutics Com New (CATX) | 1.5 | $26M | 6.3M | 4.17 | |
| Soleno Therapeutics (SLNO) | 1.3 | $22M | 652k | 33.48 | |
| Ocular Therapeutix (OCUL) | 1.3 | $22M | 2.6M | 8.47 | |
| Century Therapeutics (IPSC) | 1.1 | $20M | 8.7M | 2.26 | |
| Zura Bio Class A Ord Shs (ZURA) | 1.1 | $19M | 3.3M | 5.95 | |
| Sab Biotherapeutics Com New (SABS) | 1.0 | $17M | 4.4M | 3.83 | |
| Palisade Bio (PALI) | 0.7 | $13M | 7.2M | 1.75 | |
| Karyopharm Therapeutics Com New (KPTI) | 0.6 | $11M | 2.0M | 5.57 | |
| Inhibikase Therapeutics Com New (IKT) | 0.5 | $9.1M | 5.4M | 1.68 | |
| An2 Therapeutics (ANTX) | 0.5 | $8.0M | 2.3M | 3.42 | |
| Pepgen (PEPG) | 0.5 | $7.9M | 4.5M | 1.77 | |
| Avalo Therapeutics Com New (AVTX) | 0.4 | $7.2M | 483k | 14.93 | |
| Helix Acquisition Corp Iii Usd Cl A Ord Shs | 0.3 | $5.1M | 500k | 10.16 | |
| Athira Pharma (LONA) | 0.3 | $4.8M | 464k | 10.28 | |
| Relmada Therapeutics (RLMD) | 0.3 | $4.4M | 634k | 6.96 |
